SCHEMBL8237680

SCHEMBL8237680

CC1CN(CC2CCOCC2)CC(C)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 3/20 0.46
▸ SCN1A P35498 1/20 0.36
▸ SCN4A P35499 1/20 0.36
▸ SCN7A Q01118 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ SCN5A Q14524 1/20 0.36
▸ SCN9A Q15858 1/20 0.36
▸ SCN2A Q99250 1/20 0.36
▸ SCN3A Q9NY46 1/20 0.36
▸ SCN11A Q9UI33 1/20 0.36
▸ SCN8A Q9UQD0 1/20 0.36
▸ SCN10A Q9Y5Y9 1/20 0.36
▸ ACHE P22303 2/20 0.33
▸ CHRM2 P08172 4/20 0.33
▸ CHRM4 P08173 4/20 0.33
▸ PDE9A O76083 1/20 0.32
▸ OPRM1 P35372 2/20 0.32
▸ CACNA1G O43497 1/20 0.32
▸ CACNA1H O95180 1/20 0.32
▸ CCNT1 O60563 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30616172 1.00 GBA1 (0.46) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL23963905 0.82 GBA1 (0.50) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL2796612 0.78 GBA1 (0.49) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL3395904 0.77 NCF1 (0.42) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL18099389 0.74 GBA1 (0.50) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL18390909 0.73 ACHE (0.50) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL17285960 0.73 GBA1 (0.46) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL24733588 0.73 GBA1 (0.43) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL23520071 0.72 GBA1 (0.49) GBA1SCN1ASCN4ASCN7AKCNH2
SCHEMBL23519988 0.72 GBA1 (0.49) GBA1SCN1ASCN4ASCN7AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221603-A1 HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2009-09-03 — — US disclosed
US-20090221603-A1 HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2009-09-03 — — US disclosed
WO-2007071035-A1 HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2007-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221603-A1 HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS RYR2, CACNA1E, RYR1 GBA1 3721/4885SCN1A 101/4885SCN4A 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback